Full agonist opioid prescribing by primary care clinicians after buprenorphine training

References

• Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007–2012. Amer J Prev Med. 2015;49(3):409–413.
   PubMed Web of Science ®Google Scholar
• Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217.
   PubMed Web of Science ®Google Scholar
• Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: what actually works? A systematic review. PLoS One. 2017;12(10):e0186315.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–63.
   PubMed Web of Science ®Google Scholar
• Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Rev Psychiatry. 2015;3:63–75.
   Google Scholar
• Levin FR, Bisaga A, Sullivan MA, Williams AR, Cates-Wessel K. A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. Am J Addict. 2016;25(8):603–609.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Mannelli P, Sullivan MA, et al. Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies. Am J Addict. 2018;27(3):177–187.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine. Medication-Assisted Treatment for Opioid Use Disorder: Proceedings of a Workshop—in Brief. Washington, DC: The National Academies Press; 2018.
   Google Scholar
• Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–1212.
   PubMed Web of Science ®Google Scholar
• Hancock C, Mennenga H, King K, Andrilla H, Larson E, Schou P. Treating the rural opioid epidemic. National Rural Health Assoicaiton Policy Brief; 2017. https://www.ruralhealthweb.org/NRHA/media/Emerge_NRHA/Advocacy/Policy%20documents/Treating-the-Rural-Opioid-Epidemic_Feb-2017_NRHA-Policy-Paper.pdf. Accessed September 16, 2019.
   Google Scholar
• Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders. Substance Abuse. 2016;37(1):20–24.
   PubMed Web of Science ®Google Scholar
• Komaromy M, Bartlett J, Manis K, Arora S. Enhanced primary care treatment of behavioral disorders with ECHO case-based learning. Psychiatr Serv. 2017;68(9):873–875.
   PubMed Web of Science ®Google Scholar
• Agley J, Adams ZW, Hulvershorn LA. Extension for Community Healthcare Outcomes (ECHO) as a tool for continuing medical education on opioid use disorder and comorbidities. Addiction. 2019;114 (3):573–574.
   PubMed Web of Science ®Google Scholar
• Korthuis PT, McCarty D, Weimer M, et al. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med. 2017;166(4):268–278.
   PubMed Web of Science ®Google Scholar
• Zhou C, Crawford A, Serhal E, Kurdyak P, Sockalingam S. The impact of project ECHO on participant and patient outcomes: a systematic review. Acad Med. 2016;91(10):1439–1461.
   PubMed Web of Science ®Google Scholar
• Sockalingam S, Arena A, Serhal E, Mohri L, Alloo J, Crawford A. Building provincial mental health capacity in primary care: an evaluation of a project ECHO Mental Health Program. Acad Psychiatry. 2018;42(4):451–457.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624–1645.
   PubMed Web of Science ®Google Scholar
• Lowenstein M, Grande D, Delgado MK. Opioid prescribing limits for acute pain – striking the right balance. N Engl J Med. 2018;379(6):504–506.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM. Changing the conversation about opioid tapering. Ann Intern Med. 2017;167(3):208–209.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med. 2019;380(24):2285–2287.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Golden J, Fryer J, Chan R, Feely J. Prescribers prefer people: the sources of information used by doctors for prescribing suggest that the medium is more important than the message. Br J Clin Pharmacol. 2001;51(2):184–189.
   PubMed Web of Science ®Google Scholar
• Flodgren G, Parmelli E, Doumit G, et al. Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2011;10(8):CD000125.
   Google Scholar
• Dunn AG, Braithwaite J, Gallego B, Day RO, Runciman W, Coiera E. Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model. BMC Health Serv Res. 2012;10(12):248.
   Google Scholar
• Lubloy A. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14:469.
   PubMed Web of Science ®Google Scholar
• Poghosyan L, Lucero RJ, Knutson AR, Friedberg M, Poghosyan H. Social networks in health care teams: evidence from the United States. J of Health Org and Mgt. 2016;30(7):1119–1139.
   PubMed Web of Science ®Google Scholar
• Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B, Hal Johnson Consulting and Division of Disease Control and Health Promotion, Florida Department of Health. Decline in drug overdose deaths after state policy changes – Florida, 2010–2012. MMWR Morb. Mortal. Wkly. Rep. 2014;63(26):569–574.
   PubMed Web of Science ®Google Scholar
• Soeffling JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37(4):426–430.
   PubMed Web of Science ®Google Scholar
• Dick AW, Pacula RL, Gordon AJ, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. Health Affairs. 2015;34(6):1028–1034.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Doyle E, Kreiner PW, et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alc Dependence. 2017;181:213–218.
   PubMed Web of Science ®Google Scholar
• New York State Department of Health. New York state opioid annual data report; 2018. https://health.ny.gov/statistics/opioid/data/pdf/nys_opioid_annual_report_2018.pdf. Accessed August 30, 2019.
   Google Scholar
• New York State Department of Health. County opioid quarterly report for New York state counties – Published July 2019. (PDF) (Data in excel). https://www.health.ny.gov.‹statistics‹opioid‹quarterly_archive. Accessed August 30, 2019.
   Google Scholar
• National Center for Injury Prevention and Control. CDC compilation of benzodiazepines, muscle relaxants, stimulants, zolpidem, and opioid analgesics with oral morphine milligram equivalent conversion factors, 2017. version. Atlanta, GA: Centers for Disease Control and Prevention; https://www.cdc.gov/drugoverdose/resources/data.html. Accessed June 15, 2019.
   Google Scholar
• Guy GP, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. Mmwr Morb Mortal Wkly Rep. 2017;66:697–704.
   PubMed Web of Science ®Google Scholar
• McCalmont JC, Jones KD, Bennett RM, Friend R. Does familiarity with CDC guidelines, continuing education, and provider characteristics influence adherence to chronic pain management practices and opioid prescribing? J Opioid Manag. 2018;14(2):103–116.
   PubMedGoogle Scholar
• Wakeman SE, Pham-Kanter G, Donelan K. Attitudes, practices, and preparedness to care for patients with substance use disorder: results from a survey of general internists. Substance Abuse. 2016;37(4):635–641.
   PubMed Web of Science ®Google Scholar
• Nahin RL, Sayer B, Stussman BJ, Feinberg TM. Eighteen-year trends in the prevalence of, and health care use for, noncancer pain in the United States: data from the medical expenditure panel survey. J Pain. 2019; 20(7):796–809.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. US Food and Drug Administration Safety Announcement 4 9 2019. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. https://www.fda.gov/Drugs/DrugSafety/ucm635038.htm. Accessed April 24, 2019.
   Google Scholar
• Sharfstein JM, Olsen Y. Lessons learned from the opioid epidemic. JAMA. 2019;322(9):809–810.
   PubMed Web of Science ®Google Scholar